146 related articles for article (PubMed ID: 32244416)
1. Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab.
Šalaševičius L; Vaitkevičienė GE; Pasaulienė R; Kiudelienė R; Ivanauskaitė-Didžiokienė E; Vajauskas D; Jurkienė N; Rascon J
Medicina (Kaunas); 2020 Mar; 56(4):. PubMed ID: 32244416
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
3. Early
Chen A; Mokrane FZ; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Dulery R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Armand P; Houot R; Dercle L
J Nucl Med; 2020 May; 61(5):649-654. PubMed ID: 31628220
[TBL] [Abstract][Full Text] [Related]
4. Performance of CT Compared with
Mokrane FZ; Chen A; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Duléry R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Houot R; Dercle L
Radiology; 2020 Jun; 295(3):651-661. PubMed ID: 32286191
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
7. Multi-Organ Failure as the Initial Presentation of Lymphocyte-Depleted Hodgkin Lymphoma in Two Patients with Human Immunodeficiency Virus.
Ding J; Kumar AJ; Wilding E; Lee ST; Law JY
Acta Haematol; 2020; 143(2):184-188. PubMed ID: 31597150
[TBL] [Abstract][Full Text] [Related]
8. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
9. HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab.
Chang E; Rivero G; Patel NR; Chiao EY; Lai S; Bajaj K; Mbue JE; Yellapragada SV
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e143-e146. PubMed ID: 29342442
[No Abstract] [Full Text] [Related]
10. Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
Wang X; Ludwig EA; Passarell J; Bello A; Roy A; Hruska MW
J Clin Pharmacol; 2019 Mar; 59(3):364-373. PubMed ID: 30339279
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study.
Amraee A; Evazi MR; Shakeri M; Roozbeh N; Ghazanfarpour M; Ghorbani M; Ansari J; Darvish L
Clin Transl Oncol; 2019 Aug; 21(8):1093-1103. PubMed ID: 30739242
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab for Methotrexate-associated Classic Hodgkin's Lymphoma in a Rheumatoid Arthritis Patient.
Tanaka K; Kuboki M; Koi S; Toyota S
Intern Med; 2020 Mar; 59(6):829-833. PubMed ID: 31761888
[TBL] [Abstract][Full Text] [Related]
13. Multi-organ graft-versus-host disease after nivolumab for relapsed Hodgkin lymphoma: the role of plasma exchange.
Amerikanou R; Neill L; Shafat M; Roddy H; Hyare H; Hughes S; Thomson K; Peggs KS; Laurence A; O'Reilly M; Roddie C
Lancet Haematol; 2021 Nov; 8(11):e862. PubMed ID: 34715051
[No Abstract] [Full Text] [Related]
14. Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation.
Steinerová K; Jindra P; Lysák D; Karas M
Klin Onkol; 2019; 32(1):66-69. PubMed ID: 30764632
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab induces impressive responses in relapsed/refractory classic Hodgkin lymphoma: Single institutional experience.
Dada R; Zabani Y
J Oncol Pharm Pract; 2019 Oct; 25(7):1586-1589. PubMed ID: 30253728
[TBL] [Abstract][Full Text] [Related]
16. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
[TBL] [Abstract][Full Text] [Related]
17. Interstitial nephritis associated with nivolumab in a patient with hodgkin lymphoma.
Oliveira DS; Mesquita JL; Garcia YDO; Rosales YMZ; Lemes RPG; Rocha Filho FD; Fernandes PFCBC; Duarte PMA; Pitombeira MDS; Duarte FB
Rev Assoc Med Bras (1992); 2019 Aug; 65(7):934-936. PubMed ID: 31389500
[No Abstract] [Full Text] [Related]
18. Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma.
Serrao A; Canichella M; De Luca ML; Tartaglia G; Annechini G; D'Elia GM; Pulsoni A
Ann Hematol; 2019 Jun; 98(6):1505-1506. PubMed ID: 30413900
[No Abstract] [Full Text] [Related]
19. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
Dada R; Zekri J
J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
[TBL] [Abstract][Full Text] [Related]
20. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
